Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL

---

Longo Benedetto

Tor Vergata University of Rome, Italy

: J Plast Surg Cosmetol

Abstract

---

Summary: Shared strategies and correct information are essential to guide physicians in the management of such an uncommon disease as Breast Implant–Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). A systematic review of the literature was performed to collect the most relevant evidence on BIA-ALCL reported cases. A panel of multidisciplinary experts discussed the scientific evidence on BIA-ALCL, and updated consensus recommendations were developed through the Delphi process. The lastest reported Italian incidence of BIA-ALCL is 3.5 per 100.000 implanted patients (95 percent CI, 1.36 to 5.78), and the disease counts over 1216 cases worldwide as of June 2022. The most common presentation symptom is a late onset seroma followed by a palpable breast mass. In the event of a suspicious case, ultrasound-guided fine-needle aspiration should be the first step in evaluation, followed by cytologic and immunohistochemical examination. In patients with confirmed diagnosis of BIA-ALCL confined to the capsule, the en-bloc capsulectomy should be performed, followed by immediate autologous reconstruction, while delayed reconstruction applies for disseminate disease or radically unresectable tumor. Nevertheless, a multidisciplinary team approach is essential for the correct management of this patholog. Recent Publications: 1. Facial transplantation: Nonimmune-related hyperacute graft failure. ISBN: 978-303121520-9;978-303121519-3 2. Comment on “BIA-ALCL: Comparing the Risk Profiles of Smooth and Textured Breast Implants” ISSN: 0364216X 3. Contrast-enhanced Ultrasound Using Intradermal Microbubble Sulfur Hexafluoride for Identification of Sentinel Lymph Nodes During Breast Cancer Surgery: A Clinical Trial. ISSN: 02507005.

Biography

---